Abstract
We studied pubertal status and ovarian function in 21 girls aged 11–21 years who had earlier received 1.2–13 years (median 7 years) high-dose chemotherapy and autologous BMT without TBI for malignant tumors. Ten of them were given busulfan (600 mg/m2) and melphalan (140 mg/m2) with or without cyclophosphamide (3.6 g/m2). Eleven others did not receive busulfan. Twelve girls (57%) had clinical and hormonal evidence of ovarian failure. Among nine others who had completed normal puberty, six had normal gonadotropin levels, one had elevated gonadotropin levels and two had gonadotropin levels at the upper limit of normal. The 10 girls who received busulfan all developed severe and persistent ovarian failure. High-dose busulfan is therefore a major cause of ovarian failure even when given in the prepubertal period. These findings emphasize the need for long-term endocrine follow-up of these patients in order to initiate estrogen replacement therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Teinturier, C., Hartmann, O., Valteau-Couanet, D. et al. Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure. Bone Marrow Transplant 22, 989–994 (1998). https://doi.org/10.1038/sj.bmt.1701483
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1701483
Keywords
This article is cited by
-
Premature ovarian insufficiency in female adolescent and young adult survivors of non-gynecological cancers: a population-based cohort study
Reproductive Health (2023)
-
Late endocrine effects after hematopoietic stem cell transplantation in children with nonmalignant diseases
Bone Marrow Transplantation (2022)
-
The effect of hematopoietic stem cell transplantation on fertility and strategies for improvement
Bone Marrow Transplantation (2022)
-
Long-term follow-up of high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell transplantation rescue
Bone Marrow Transplantation (2021)
-
Anti-Müllerian hormone and Inhibin B after stem cell transplant in childhood: a comparison of myeloablative, reduced intensity and treosulfan-based chemotherapy regimens
Bone Marrow Transplantation (2020)